

# Albireo Pharma Inc (ALBO) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/AFD8536CDFBEN.html>

Date: September 2021

Pages: 49

Price: US\$ 125.00 (Single User License)

ID: AFD8536CDFBEN

## Abstracts

Albireo Pharma Inc (ALBO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

## Highlights

Albireo Pharma Inc (Albireo), formerly Biodel Inc, focuses on the development and commercialization of novel bile acid modulators for treatment of orphan pediatric liver diseases, gastrointestinal (GI) disorders and other diseases. Its pipeline products include odevixibat (A4250) intended for treatment of progressive familial intrahepatic cholestasis (PFIC), biliary atresia, alagille syndrome and other cholestaticc; A3384 for bile acid malabsorption; and elobixibat for nonalcoholic steatohepatitis (NASH). Elobixibat is approved in Japan for the treatment of chronic constipation. The company is investigating bile acid modulator for nonalcoholic steatohepatitis (NASH) and other preclinical trials for the treatment of adult liver diseases. It operates in the US, the UK, and Sweden. Albireo is headquartered in Boston, Massachusetts, the US.

### Albireo Pharma Inc Key Recent Developments

Sep 08,2021: Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)  
Aug 05,2021: Albireo Reports Q2 Financial Results and Business Update  
Jun 30,2021: Albireo to Report Second Quarter 2021 Financial Results on August 5  
Jun 24,2021: Albireo to Present at Piper Sandler's Virtual EASL Takeaway Day  
May 06,2021: Albireo Reports Q1 Financial Results and Business Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios

and charts are incorporated in the profile to assist your academic or business research needs.

**Note:** Some sections may be missing if data is unavailable for the company

## Contents

### **SECTION 1 - ABOUT THE COMPANY**

Albireo Pharma Inc - Key Facts  
Albireo Pharma Inc - Key Employees  
Albireo Pharma Inc - Key Employee Biographies  
Albireo Pharma Inc - Major Products and Services  
Albireo Pharma Inc - History  
Albireo Pharma Inc - Company Statement  
Albireo Pharma Inc - Locations And Subsidiaries  
Head Office  
Other Locations & Subsidiaries

### **SECTION 2 – COMPANY ANALYSIS**

Company Overview  
Albireo Pharma Inc - Business Description  
R&D Overview  
Albireo Pharma Inc - Corporate Strategy  
Albireo Pharma Inc - SWOT Analysis  
SWOT Analysis - Overview  
Albireo Pharma Inc - Strengths  
Albireo Pharma Inc - Weaknesses  
Albireo Pharma Inc - Opportunities  
Albireo Pharma Inc - Threats  
Albireo Pharma Inc - Key Competitors

### **SECTION 3 – COMPANY FINANCIAL RATIOS**

Financial Ratios - Capital Market Ratios  
Financial Ratios - Annual Ratios  
Performance Chart  
Financial Performance  
Financial Ratios - Interim Ratios  
Financial Ratios - Ratio Charts

### **SECTION 4 – COMPANY’S LIFESCENCES FINANCIAL DEALS AND ALLIANCES**

Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021  
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021  
Albireo Pharma Inc, Recent Deals Summary

## **SECTION 5 – COMPANY’S RECENT DEVELOPMENTS**

Aug 05, 2021: Albireo Reports Q2 Financial Results and Business Update  
Jun 30, 2021: Albireo to Report Second Quarter 2021 Financial Results on August  
Jun 24, 2021: Albireo to Present at Piper Sandler’s Virtual EASL Takeaway Day  
May 06, 2021: Albireo Reports Q1 Financial Results and Business Update  
Apr 13, 2021: Albireo Expands Leadership with Joan Connolly as Chief Technology Officer  
Apr 06, 2021: Albireo to Participate in the Needham 20th Annual Virtual Healthcare Conference  
Feb 25, 2021: Albireo reports Q4 and year-end 2020 financial results and business update  
Feb 23, 2021: Albireo to Participate in Cowen and H.C. Wainwright Global Investor Conferences  
Feb 18, 2021: Albireo to Report Q4 and Year-End 2020 Financial Results on February  
Jan 05, 2021: Albireo to Participate in H.C. Wainwright BioConnect and LifeSci Advisors Investor Conferences

## **SECTION 6 – APPENDIX**

Methodology  
Ratio Definitions  
About GlobalData  
Contact Us  
Disclaimer

## List Of Tables

### LIST OF TABLES

Albireo Pharma Inc, Key Facts  
Albireo Pharma Inc, Key Employees  
Albireo Pharma Inc, Key Employee Biographies  
Albireo Pharma Inc, Major Products and Services  
Albireo Pharma Inc, History  
Albireo Pharma Inc, Subsidiaries  
Albireo Pharma Inc, Key Competitors  
Albireo Pharma Inc, Ratios based on current share price  
Albireo Pharma Inc, Annual Ratios  
Albireo Pharma Inc, Annual Ratios (Cont...1)  
Albireo Pharma Inc, Interim Ratios  
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021  
Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021  
Albireo Pharma Inc, Recent Deals Summary  
Currency Codes  
Capital Market Ratios  
Equity Ratios  
Profitability Ratios  
Cost Ratios  
Liquidity Ratios  
Leverage Ratios  
Efficiency Ratios

## List Of Figures

### LIST OF FIGURES

Albireo Pharma Inc, Performance Chart (2016 - 2020)

Albireo Pharma Inc, Ratio Charts

Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Albireo Pharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021



## I would like to order

Product name: Albireo Pharma Inc (ALBO) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/AFD8536CDFBEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AFD8536CDFBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970